Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of businesses that shrink and lose money, and Maravai's filed results show exactly that. In fiscal 2023, the year ended 2023-12-31, revenue was $288.9 million and net loss was $119.0 million, or diluted EPS -$0.90. In fiscal 2024, revenue fell to $259.2 million and net loss widened to $144.8 million, or diluted EPS -$1.05. In fiscal 2025, revenue fell again to $185.7 million, with a net loss of $130.8 million, or diluted EPS -$0.90. That is not a durable compounding machine; it is a turnaround. The latest fiscal Q2 2026, the quarter ended 2026-06-30, showed revenue of $51.4 million and a net loss of $12.4 million, or diluted EPS -$0.08, better than fiscal Q2 2025, the quarter ended 2025-06-30, which had $47.4 million revenue and a $39.6 million net loss. Still, fiscal Q1 2026, the quarter ended 2026-03-31, had $65.8 million revenue and a $3.7 million net loss, so the trend is uneven. At the close on 2026-10-13, the $6.53 price gives a $966.4 million market cap. FairStock's calculations show P/B 4.77, negative P/E -12.32, ROE -33.05%, ROCE -5.71%, debt-to-equity 0.61, TTM free cash flow -$35.8 million, and FCF yield -3.7%. A Piotroski F-Score of 3/9 and FairStock Score of 25/100 confirm weak financial momentum. The Lynch category is TURNAROUND, based on a loss in the latest year after earlier profits, though the filed annual figures show losses in each of the last three years. I would need to see sustained revenue recovery and positive free cash flow before treating this as a Graham-style bargain. The balance sheet is not overleveraged, but paying nearly five times book for a loss-making, shrinking business is not my idea of margin of safety.

In plain English: Maravai makes products used in drug, vaccine, and gene-therapy development. The business has been losing money, sales have shrunk from prior years, and it is burning cash. At $6.53 a share, the price looks high compared with its assets and its recent losses, so on these numbers it does not look cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer